CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The RSUs vest over four years with 25% of the RSUs vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to continued service through each applicable vesting date. The stock options vest over four years with 25% of the stock options vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting on an equal monthly basis over the following 36 months, subject to continued service through each applicable vesting date.
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com.
This press release includes forward-looking statements, including statements regarding CareDx’s employees and inducement equity incentive plans. These forward-looking statements are based upon information that is currently available to CareDx, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with CareDx’s employees and equity plans, and additional risks set forth in CareDx’s filings with the Securities and Exchange Commission. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Commercial Officer
Source: CareDx, Inc.